Nanobiotix Shares Drop Nearly 2%, Among the Largest Declines in the SBF 120
The French biotech continues another session in the red as the Parisian market also declines. The movement is a continuation of a significant pullback that began after the historic high recorded in mid-May. However, the annual performance remains exceptional.
A Measured Decline that Extends the Digestion of the Annual Rally
Nanobiotix shares are down 1.87% at €30.38 during the session, with the SBF 120 down by 0.45%. The stock ranks at the lower end of the broad Parisian index. The consolidation phase that began after the mid-May peak continues, even as the twelve-month performance exceeds 631%. The biotech sector context in Paris remains mixed, with a decline in Sanofi (-0.95%) and Eurofins Scientific (-0.49%), while the CAC 40 is down 0.48%.
Below the 20-Day Moving Average, but Well Above the 200-Day Average
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
In terms of technical benchmarks, the price is 17.42% below its 20-day moving average (€36.79) and 3.95% below its 50-day moving average (€31.63), indicating a short-term loss of momentum. The RSI at 43 remains in a neutral zone, with no significant signs of selling exhaustion.
The magnitude of the annual rally remains evident: the stock maintains a gap of more than 40% above its 200-day moving average (€21.61). The identified support at €26.52 remains distant from the current price.
On the fundamentals, the early June published preliminary Phase 2 results of JNJ-1900 (NBTXR3), combined with a strengthened net cash position of €42.1 million as of March 31, have provided a recent factual basis. The next technical milestone to watch remains the 50-day moving average, which the price has approached.
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 3,6 millions d'euros
Quarterly revenue: 3,6 millions d'euros
Net income: -34,3 millions d'euros
Guidance from the release
« la Société estime qu'elle disposera des liquidités suffisantes pour faire face à ses obligations financières […] pendant au moins les 12 prochains mois […] pas de doute substantiel quant à la capacité de la Société à poursuivre son activité » ; CP du 24/09 : trésorerie de 110,9 M€ « permettront de financer ses opérations jusqu'en 2029 »
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
